Artificial Intelligence
Asia-Pacific Healthcare AI Market Outlook 2019E-2025E
Dublin, Feb. 01, 2021 (GLOBE NEWSWIRE) — The “APAC Healthcare AI Market Outlook to 2025 – by Applications, by Countries, by End Users & by Technologies and Current Investment Scenario” report has been added to ResearchAndMarkets.com’s offering.
This report will particularly help the readers to identify the ongoing trends in the industry and anticipated growth in the future depending upon changing industry dynamics in upcoming years.
The report also covers emerging growth drivers and trends; innovation, adoption and application gap in comparison to US and Europe; case studies on various healthcare application areas and competitive landscape of players in the market with special focus on IBM, NVIDIA Corporation, Intel, Microsoft Corporation, iCarbonX, Alphabet Inc., Next IT Verint Corporation, Welltok Incorporation, Oncora Medical, Entilic Incorporation, Koninklijke Philips and General Vision.
The interpretation explores investment trends in the market, major funding opportunities by stage, potential markets of investment activity along with future outlook & projections highlighting the major opportunities & cautions to the reader.
Key Topics Covered: 1. Executive Summary
2. Research Methodology 3. APAC AI in Healthcare Value Chain & Ecosystem
4. APAC AI in Healthcare Market Size Analysis, 2013- 2018
5. APAC Healthcare AI Market Segmentation, 2013-2025E 5.4. By Technology (Deep Learning, Querying Method, Natural Language Processing & Context Aware Processing), 2013-2023E
6. Innovation, Adoption and Application Gap – Comparison of APAC with Europe & US
7. Regulatory Framework in APAC AI in Healthcare Market
8. Case Studies on Various Application Areas of AI in Healthcare, 2013-2018 9. Competitive Landscape in APAC AI in Healthcare Market, 2018 10. Company Profiling of Major Players Operating in APAC Artificial Intelligence in Healthcare Market (Including Company Overview, Software Offerings, Applications, Business Strategies, Partnerships, Products Offered, Watson in APAC, Challenges Faced etc.) 11. Investment Sceanrio-Heathcare in AI, 2018 12. Healthcare AI Market Mapping 13. Markets of Investment Activity 14. Future Market Sizing Analysis, 2019E-2025E For more information about this report visit https://www.researchandmarkets.com/r/3zaf3d
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
2.1. Market Definitions
2.2. Abbreviations
2.3. Consolidated Research Approach
2.4. Market Sizing Approach
2.5. Market Limitations
2.6. Final Conclusion
5.1. By Application, 2013-2025E
5.2. By End User (Hospitals/Clinics/Healthcare Providers, Medical Devices Companies, Pharmaceuticals, Biotechnology Companies & Others), 2013-2025E
5.3. By Country (Japan, China, Australia, India, Singapore & Rest of APAC), 2013-2023E
8.1. Automated Report Generating Model
8.2. Hospital Patient Management System
8.3. Digital Pathology
8.4. Face Recognition in Healthcare
8.5. Converting Paperwork into Digital Data
8.6. Healthcare Vascular Disrupting Agent
8.7. Counterfeit Medicine Analysis
8.8. Medical Treatment Recommendations
8.9. Predicting Illness and Patient Outcomes
8.10. Text Classification and Mining for Biomedical Literature
8.11. Portable Ultrasound Devices
8.12. Methods of Monitoring Vitals
8.13. Drug Discovery
8.14. Biomarker Discovery
9.1. Competition Scenario in APAC AI in Healthcare Market, 2018
9.2. Strengths and Weaknesses Of Major Players, 2018
10.1.1. IBM
10.2. NVIDIA Corporation
10.3. Intel
10.4. Microsoft Corporation
10.5. iCarbonX
10.6. Alphabet Inc. (Google Inc)
10.7. Next-IT Verint Corporation
10.8. Welltok Incorporation
10.9. Oncora Medical
10.10. Entilic Incorporation
10.11. Koninklijke Philips
10.12. General Vision
11.1. List of Companies By Public, Acquired and Unicorn, 2018
11.2. Competition Analysis & Investment Outlook by Sector
11.2.1. List of Companies By Biopharma (by Therapy)
11.2.2. List of Companies By Healthcare Analytics
11.2.3. List of Companies By Clinical Analytics
11.2.4. List of Companies By Diagnostics (by Disease)
11.2.5. List of Companies By Consumer HealthTech
11.2.6. List of Companies By Healthcare IT
11.2.7. List of Companies Diagnostics (By Technology)
11.2.8. List of Companies By Medical Devices
11.2.9. List of Companies By Research and Development
11.3. Major Funding By Stage (Late, Early and Seed), June 2017- June 2019
11.4. Investment Trends
12.1. Biopharma (By Theraphy)
12.2. Healthcare Analytics
12.3. Biopharma (by Disease)
12.4. Diagnostics (By Disease)
12.5. Consumer HealthTech
12.6. By Fitness and Wellness Tech
12.7. By Healthcare IT
12.8. Diagnostics (by Technology)
12.9. By Medical Devices
12.10. Life Sciences Tech
12.11. Biotech R&D
12.12. Biopharma Outsourcing
12.13. Genomics
12.14. Assistive Tech
12.15. Others
13.1. Suite
13.2. Sequencing Analysis
13.3. Cheminformatics
13.4. Patient Health
13.5. Aging
13.6. AI
13.7. Virtual Care
13.8. Access Solutions
13.9. WorkFlow Optimization
13.10. Disease Agnostic AI
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Artificial Intelligence
Northern Data Group is first in Europe to acquire NVIDIA H200 GPUs
First in Europe to acquire NVIDIA H200 GPUs – currently the most powerful GPUs on the market The deployment further expands the Group’s Generative AI CSP offering, already the largest in Europe Further demonstration of the Group’s continued commitment to providing best-in-class technologies FRANKFURT, Germany, July 1, 2024 /PRNewswire/ — Northern Data Group (Ticker symbol German stock market: NB2, ISIN: DE000A0SMU87), a leading provider of High-Performance Computing (HPC) solutions, today announces it has purchased NVIDIA H200 GPUs through a newly established partnership with Supermicro, a global leader in Application-Optimized Total IT Solutions.
Northern Data Group’s cloud platform, Taiga Cloud will be the first Cloud Service Provider (CSP) in Europe to offer access to the H200 GPU hardware, with delivery and deployment scheduled for Q4 2024. The partnership with Supermicro for the NVIDIA H200 GPUs will further build its HPC solutions and complement its existing offering of best-in-class GenAI technologies.
This purchase of the H200 GPUs demonstrates Northern Data Group’s commitment to offering the best-in-class technology to its customers, as it continues to expand its cloud solutions offering, while also maintaining its position as Europe’s first and largest dedicated Generative AI Cloud Service Provider.
The first full island of over 2,000 NVIDIA H200 GPUs utilizing BlueField-3 data processing units (DPUs) and NVIDIA Mellanox CX7 NICs, to deliver 32 petaFLOPS of performance. The configuration of NVIDIA-referenced architecture allows customers to access more bandwidth, faster, and more efficient data storage access. The H200 GPUs will be housed in one of Northern Data Group’s European data centers, powered by carbon-free, renewable energy and boast a Power Usage Effectiveness ratio of less than 1.2.
Aroosh Thillainathan, Founder and CEO, Northern Data Group, commented:
“Our GenAI platform is constantly evolving and we are proud to collaborate with Supermicro to be the first in Europe to offer access to NVIDIA H200 GPUs. This is testament to our commitment to continually offer industry-leading, next-generation solutions.
“As an Elite Partner of NVIDIA, we are proud to continue to offer cutting-edge technology, deployed in line with recommended architecture references to maximize the technology.”
Vik Malyala, President & Managing Director, EMEA; SVP, Technology & AI, Supermicro commented:
“We are excited to collaborate with Northern Data Group to expand its GenAI Cloud offering to include Supermicro GPU servers based on latest Nvidia H200 HGX GPUs. Supermicro is fully committed to delivering most performant and energy efficient AI infrastructure and solutions, and this collaboration will accelerate availability and bring the best value for customers in Europe.”
About Northern Data Group:
Northern Data Group (ETR: NB2) is a leading provider of High-Performance Computing (HPC) solutions to businesses and research institutions, utilizing GPU- and ASIC-based solutions. Our flexible compute power fuels innovation in our three core business platforms: Taiga Cloud, Ardent Data Centers, and Peak Mining. Through our HPC solutions, we pioneer ambitious computing innovation that drives progress in the AI, ML and Generative AI industries. Our close collaboration with industry-leading manufacturers including Gigabyte, AMD, and NVIDIA is fundamental to the acceleration of innovation across sectors including life sciences, financial services, and energy.
About Taiga Cloud:
Taiga Cloud, a Northern Data Group platform, is Europe’s first and largest Generative AI Cloud Service Provider. We provide a flexible, secure and compliant cloud-based ultra-fast GPU Network, engineered to meet organizations’ most ambitious compute needs. Taiga Cloud recognizes that high-intensity, large-scale processing power is crucial for accelerating Generative AI models and research which will deliver a new era of technological breakthroughs. Taiga’s energy-efficient Cloud is powered by Europe’s largest cluster of NVIDIA A100 Tensor Core and H100 Tensor Core GPUs, helping enable organizations to accelerate AI and ML innovation on demand, with technology that is fully scalable.
View original content:https://www.prnewswire.co.uk/news-releases/northern-data-group-is-first-in-europe-to-acquire-nvidia-h200-gpus-302185926.html
Artificial Intelligence
Dawn Health and Merck are collaborating to support Growth Disorders care
COPENHAGEN, Denmark, July 1, 2024 /PRNewswire/ — Dawn Health, the digital health company pioneering patient-first innovation, has announced they are working with leading global pharmaceutical company, Merck, on a digital solution for Growth Hormone Disorders (GHD).
Over the next two years, they will join forces to deliver a cutting-edge, user-centric digital platform, designed to help improve the lives of tens of thousands of patients across more than 40 countries.
By harnessing the latest AI technologies, the collaboration will also involve exploring the integration of features such as growth predictions and advanced personalization into the digital product, with excitement about AI and its potential for impact on user experience, adoption, adherence, and treatment outcomes. The digital solution will provide support to children and young adults living with GHD, as well as providing tools and support to their caregivers, both at home and in a clinical setting.
With a shared commitment to improving patient lives, the collaboration will focus on patient-centricity to deliver an intuitive, engaging product that supports users and caregivers throughout their treatment journey. This means speaking with patients to truly understand their unmet needs and how the solution can best address these, as well as hearing from caregivers and healthcare professionals about how to best empower and support those living with GHD.
The collaboration is already off to a strong start, with workshops and inspiring discussions happening between the teams at Dawn Health and Merck, as they work together to deliver a cutting-edge platform on a global scale to improve the lives of people living with Growth Hormone Disorders.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Dawn Health
Dawn Health is a global leader in digital health, specializing in the development of software as a medical device (SaMD) and digital therapeutics (DTx). Partnering with pharmaceutical companies, Dawn Health accelerates the launch of digital solutions to change the lives of people with chronic conditions.
Media Contacts
For questions about [email protected]
For questions about Dawn HealthChristopher Kold, [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/dawn-health-and-merck-are-collaborating-to-support-growth-disorders-care-302184356.html
Artificial Intelligence
Transforming Healthcare with AI: Yidu Tech’s Gong Rujing at Summer Davos
DALIAN, China, July 1, 2024 /PRNewswire/ — “AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry.” At the 15th Annual Meeting of the New Champions, also known as Summer Davos, Ms. Gong Rujing (Yingying), Chairwoman and Founder of Yidu Tech, was invited as a distinguished representative of the healthcare technology sector. She shared her unique insights into the future of AI in healthcare during the thematic dialogue on “Healthcare Analytics, Not Moving Fast Enough.”
This year marks the 10th anniversary of Yidu Tech and Ms. Gong Rujing’s decade-long dedication to the healthcare industry. From the inception of her entrepreneurial journey 10 years ago, she has been driven by the mission to leverage the power of technology to deliver precise healthcare to every individual.
Ms. Gong described the past decade as a journey filled with miracles and achievements. During this period, Yidu Tech has progressively established close collaborations with key stakeholders in the healthcare industry, including government agencies, hospitals, pharmaceutical companies, insurance firms, experts, and clinicians. As of March 31, 2024, Yidu Tech’s “AI Medical Brain” YiduCore has been authorized to process and analyze over 5 billion medical records, covering more than 2,500 hospitals.
In AI-powered clinical research, Yidu Tech has supported researchers and clinicians in producing over 240 high-level papers, accelerating the application of research outcomes. Additionally, Yidu Tech provides clinical trial services to globally renowned pharmaceutical companies, helping them optimize trial processes, reduce costs, and bring new drugs to market more swiftly, ultimately benefiting patients. In healthcare management, Yidu Tech’s AI technology plays a crucial role by analyzing vast amounts of medical data to provide comprehensive decision support to healthcare administrators, helping them optimize resource allocation and improve service efficiency.
“We are now entering a new era of AI technology.” The development of large language model technologies has opened up new possibilities across various industries. Yidu Tech has independently developed a large language model specific to the medical field and is advancing its application across the entire healthcare industry chain. The goal is to promote further progress and innovation through new AI technologies. However, Ms. Gong also emphasized that the healthcare industry is professional, complex, and sensitive, and the application of new technologies must address challenges such as data security, privacy protection, and ethics.
“Data security and privacy protection are fundamental to the development of AI technology and medical big data technology. We must ensure that all stakeholders are satisfied with compliance, security, accessibility, and privacy protection.”
“AI technology still has a long way to go.” She called on policymakers, healthcare institutions, and technology companies to work together to realize the immense potential of healthcare data. Ms. Gong highlighted that building trust is key, and enhancing data operability is essential to fully unleash the power of data. “It’s not just about better data quality; it’s about a better future for health.”
View original content:https://www.prnewswire.co.uk/news-releases/transforming-healthcare-with-ai-yidu-techs-gong-rujing-at-summer-davos-302186561.html
-
Artificial Intelligence6 days ago
Relativity Announces General Availability Date for its Generative AI-Powered Review Solution at Relativity Fest London
-
Artificial Intelligence6 days ago
SKAN, the Wellcome Sanger Institute and University of Newcastle to study early stem cell mutations in rare blood disorder
-
Artificial Intelligence6 days ago
COMPREDICT Secures $15M Series B Funding Round Led by Woven Capital
-
Artificial Intelligence6 days ago
AI Revolution Accelerates: North American Tech Companies Lead Amid Regulatory Changes
-
Artificial Intelligence3 days ago
CO2 AI Launches First Solution to Compute Product Emissions at Scale
-
Artificial Intelligence3 days ago
Asia Pacific View: Foreigners Looking for the Most Practical Smart Technology at the 2024 World Intelligence Expo
-
Artificial Intelligence3 days ago
Spotlight on Authentic AI: Developers Making Real Contributions Beyond AI Washing Claims
-
Artificial Intelligence3 days ago
North American grocery retailer digitizes stores with Pricer Plaza in 90 MSEK order